Author:
Liu Chang-Hsien,Kuo Shih-Ming,Gao Hong-Wei,Hsu Yu-Juei
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference13 articles.
1. Brown JM (1993) SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67(6):1163–1170
2. Gandara DR, Lara PN Jr, Goldberg Z, Le QT, Mack PC, Lau DH, Gumerlock PH (2002) Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol 29(1 Suppl 4):102–109. https://doi.org/10.1053/sonc.2002.31531
3. Senan S, Rampling R, Graham MA, Wilson PJ, Robin H, Eckardt NA, Lawson N, McDonald AD, Roemeling RV, Workman P, Kaye SB (1997) Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res 3(1):31–38
4. Covans A, Blessing J, Bender D, Mannel R, Morgan M (2006) A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 100(3):586–590. https://doi.org/10.1016/j.ygyno.2005.09.032
5. Maluf FC, Leiser AL, Aghajanian C, Sabbatini P, Pezzulli S, Chi DS, Wolf JK, Levenback C, Loh E, Spriggs DR (2006) Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. Int J Gynecol Cancer 16(3):1165–1171. https://doi.org/10.1111/j.1525-1438.2006.00454.x
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献